50534-23-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Acetamido-1-benzylpiperidine is used as a pharmaceutical compound for its analgesic and anesthetic properties, offering potential in the development of pain management and anesthetic agents.
Used in Drug Development:
4-Acetamido-1-benzylpiperidine is used as a drug precursor, indicating its potential role in the synthesis of new and improved pharmaceuticals for various medical conditions.
Used in Medicinal Chemistry Research:
4-Acetamido-1-benzylpiperidine is utilized as a subject of research in medicinal chemistry, where its specific properties and applications are explored to advance the understanding of its therapeutic potential and to develop new drugs based on its structure and function.

InChI:InChI=1/C14H20N2O/c1-12(17)15-14-7-9-16(10-8-14)11-13-5-3-2-4-6-13/h2-6,14H,7-11H2,1H3,(H,15,17)

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 

Downstream Products

• 50534-24-2 1-phenylmethyl-4-ethylaminopiperidine 
• 5810-56-0 4-(acetylamino)piperidine 
• 280111-37-7 1-benzyl-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-piperidine 
• 795310-52-0 4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-piperidine 
• 380222-94-6 9-{(3AR,4R,6S,6AS)-6-[(ethylamino)carbonyl]-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}-6-[(2,2-diphenylethyl)amino]-N-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9H-purine-2-carboxamide 
• 380221-63-6 6-[(2,2-Diphenylethyl)amino]-9-{(2R,3R,4S,5S)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-N-(2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl)-9H-purine-2-carboxamide 
• 76167-82-3 (1-Benzyl-piperidin-4-yl)-ethyl-pyrimidin-2-yl-amine; hydrochloride 
• 181579-48-6 2-{2-[(1-Benzyl-piperidin-4-yl)-ethyl-amino]-pyridin-3-ylamino}-2-methyl-propionitrile 
• 179558-71-5 1-Benzyl-4-[N-ethyl-N-(3-(1,1-dimethylethylamino)-6-chloro-2-pyridinyl)amino]piperidine 
• 1027537-87-6 1-benzyl-4-[N-ethyl-N-((3-(1,1-dimethylethylamino)-6-fluoro)-2-pyridyl)amino]piperidine 
• 181579-37-3 1-benzyl-4-[N-ethyl-N-(6-chloro-3-nitro-2-pyridinyl)amino]piperidine 
• 179557-98-3 1-Benzyl-4-[N-ethyl-N-(6-fluoro-3-(nitro)-2-pyridinyl)amino]piperidine 
• 181579-50-0 N²-(1-Benzyl-piperidin-4-yl)-N²-ethyl-6-fluoro-N³-isopropylidene-pyridine-2,3-diamine 
• 179557-48-3 1-benzyl-4-[N-ethyl-N-(3-(1,1-dimethylethylamino)-2-pyridinyl)amino]piperidine 

Relevant academic research and scientific papers

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Novel Ethanediamone Hepcidine Antagonists

The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

Route selection and process development of a multikilogram route to the inhaled A2a agonist UK-432,097

This article describes the selection, process development, and scale-up of a synthetic route to a complex nucleoside analogue, the A2a agonist UK-432,097 (1), that culminated in the manufacture of over 25 kg of the API. The key steps in the process were (1) a stereoselective glycosidation reaction; (2) a scalable bleach-TEMPO oxidation; and (3) an unusual elevated temperature crystallization process for the final API. The problems that were encountered with the scale-up of the route together with how they were overcome are also presented.

Chemical Compound

The present invention relates to 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine (I): or a pharmaceutically acceptable salt thereof, as well as processes for the preparation of this compound and its use in the treatment of CCR5 disease states.

TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY

The present invention provides compounds of formula (I) Wherein R1 , R2, R3 , R4 , Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

CHEMICAL COMPOUNDS

Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs

Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease.

2-alkylidene hydroxycumaranone derivatives

Compounds of the formula wherein R,R′, A,B,T and x have the meaning given in the specification possess uPA (urokinase-type plasminogen activator) antagonist activity and can be employed as antitumor and/or antimetastatic agents.